Brain Tumor, Recurrent

Oncology
3
Pipeline Programs
3
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

T-Therapeutics
T-TherapeuticsUK - Cambridge
2 programs
1
1
Photofrin photodynamic therapy.Phase 21 trial
PhotofrinPhase 11 trial
Active Trials
NCT01682746CompletedEst. Jun 2018
NCT01966809TerminatedEst. Dec 2017
EpicentRx
EpicentRxCA - La Jolla
1 program
1
RRx-001Phase 11 trial
Active Trials
NCT04525014TerminatedEst. Jul 2024
GT Biopharma
GT BiopharmaSAN FRANCISCO, CA
1 program
GammaTileN/A1 trial
Active Trials
NCT04427384RecruitingEst. Dec 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
T-TherapeuticsPhotofrin photodynamic therapy.
EpicentRxRRx-001
T-TherapeuticsPhotofrin
GT BiopharmaGammaTile

Clinical Trials (4)

NCT01966809T-TherapeuticsPhotofrin photodynamic therapy.

Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas

Start: Jun 2015Est. completion: Dec 2017
Phase 2Terminated

RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors

Start: Jan 2023Est. completion: Jul 2024
Phase 1Terminated

Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors

Start: Mar 2013Est. completion: Jun 2018
Phase 1Completed

Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)

Start: Sep 2020Est. completion: Dec 2028
N/ARecruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials
3 companies competing in this space